Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease

To evaluate the influence of highly active antiretroviral therapy (HAART) on the outcome of HIV-related Hodgkin's disease (HD), two groups were studied: patients without previous HAART, and patients treated with HAART previously or concomitantly with HD therapy. In the second group, the complete response was higher and the disease-free survival and overall survival probabilities were significantly longer. HAART is thus associated with an improvement in response to therapy and survival in patients with HIV-related HD.